Clinical Prevention Services (CPS)

Quarterly Surveillance Report
Table of Contents

Infectious Syphilis ................................................................. 3
  1. Infectious Syphilis case reports in BC by month ............................................. 3
  2. Infectious Syphilis case reports in BC by health authority ...................................... 4
  3. Infectious Syphilis case reports in BC by gender .................................................. 5
  4. Infectious Syphilis case reports in BC by age group .............................................. 6
  5.a. Syphilis non-prenatal testing episodes* and percent positivity in BC by month - total ...... 7
  5.b. Syphilis non-prenatal testing episodes* and percent positivity in BC by month - female .... 8
  5.c. Syphilis non-prenatal testing episodes* and percent positivity in BC by month - male ........ 9
Chlamydia ............................................................................. 10
  6. Genital and Extra-genital Chlamydia case reports in BC by month ................................ 10
  7. Genital Chlamydia case reports in BC by health authority ........................................... 11
  8. Genital Chlamydia case reports in BC by gender ...................................................... 12
  9. Extra-genital Chlamydia case reports in BC by gender .............................................. 13
 10. Genital Chlamydia case reports in BC by age group .................................................. 14
Gonorrhea ............................................................................. 15
  11. Genital and Extra-genital Gonorrhea case reports in BC by month ............................... 15
  12. Genital Gonorrhea case reports in BC by health authority ........................................... 16
  13. Genital Gonorrhea case reports in BC by gender ...................................................... 17
  14. Extra-genital Gonorrhea case reports in BC by gender .............................................. 18
  15. Genital Gonorrhea case reports in BC by age group .................................................. 19
HIV .......................................................................................... 20
  16. New HIV diagnoses in BC by month ................................................................. 20
  17. New HIV diagnoses in BC by health authority ...................................................... 21
  18. New HIV diagnoses in BC by sex .............................................................................. 22
  19. New HIV diagnoses in BC by age group ................................................................. 23
  20.a. HIV non-prenatal testing episodes* and percent positivity in BC by month - total ........ 24
  20.b. HIV non-prenatal testing episodes* and percent positivity in BC by month - female .... 25
  20.c. HIV non-prenatal testing episodes* and percent positivity in BC by month - male ........ 26
Hepatitis C ............................................................................. 27
  21. New Hepatitis C cases in BC by month ................................................................. 27
  22. New Hepatitis C cases in BC by health authority ...................................................... 28
  23. New Hepatitis C cases in BC by sex ........................................................................... 29
  24. New Hepatitis C cases in BC by age group ................................................................. 30
  25.a. HCV antibody testing episodes* and percent positivity in BC by month - total ............ 31
  25.b. HCV antibody testing episodes* and percent positivity in BC by month - female ........ 32
  25.c. HCV antibody testing episodes* and percent positivity in BC by month - male ............ 33
Active Tuberculosis ................................................................. 34
  26. Active tuberculosis case reports in BC by month ..................................................... 34
  27. Active tuberculosis case reports in BC by health authority ......................................... 35
  28. Active tuberculosis case reports in BC by sex .......................................................... 36
  29. Active tuberculosis case reports in BC by age group .................................................. 37
Latent Tuberculosis Infection ................................................... 38
  30. Latent tuberculosis infection (LTBI) treatment starts in BC by month ........................... 38
Technical Appendix .................................................................. 39
Infectious Syphilis

1. Infectious Syphilis case reports in BC by month

Preliminary data and subject to change
2. Infectious Syphilis case Reports in BC by health authority

Preliminary data and subject to change

Note: Excludes missing and unknown geography. Due to reporting delays, geographic trends should be interpreted with caution.
3. Infectious Syphilis case reports in BC by gender

![Graph showing infectious syphilis cases by gender over months and years.]

**Preliminary data and subject to change**

Note: Gender is based on the gender variable values collected in Intrahealth Profile EMR which is structured as male, female, transgender and unknown. Data shown reflects male, female, and transgender responses only.
4. Infectious Syphilis case reports in BC by age group

Preliminary data and subject to change

Note: Excludes cases where age could not be calculated due to missing date of birth.
Syphilis Testing Episodes

5.a. Syphilis non-prenatal testing episodes* and percent positivity in BC by month - total

Preliminary data and subject to change

*Testing episode = 30-day window (see technical appendix for further details).

Note: Percent positivity is calculated as the number of infectious syphilis cases over testing episodes, where a testing episode is defined as a 30-day window.
5.b. Syphilis non-prenatal testing episodes* and percent positivity in BC by month - female

Preliminary data and subject to change

*Testing episode = 30-day window (see technical appendix for further details).

Note: Percent positivity is calculated as the number of infectious syphilis cases over testing episodes, where a testing episode is defined as a 30-day window.

-The number of female syphilis non-prenatal testing episodes is based on sex reported on the laboratory requisition. The number of female infectious syphilis cases is based on gender variable values collected in Intrahealth Profile EMR.
5.c. Syphilis non-prenatal testing episodes* and percent positivity in BC by month - male

Preliminary data and subject to change

*Testing episode = 30-day window (see technical appendix for further details).

Note: Percent positivity is calculated as the number of infectious syphilis cases over testing episodes, where a testing episode is defined as a 30-day window.

-The number of male syphilis non-prenatal testing episodes is based on sex reported on the laboratory requisition. The number of male infectious syphilis cases is based on gender variable values collected in Intrahealth Profile EMR.
Chlamydia

6. Genital and Extra-genital Chlamydia case reports in BC by month

Preliminary data and subject to change
7. Genital Chlamydia case reports in BC by health authority

Preliminary data and subject to change

Note: Excludes missing and unknown geography.
8. Genital Chlamydia case reports in BC by gender

Preliminary data and subject to change

Note: Gender is based on the gender variable values collected in Intrahealth Profile EMR which is structured as male, female, transgender and unknown. Data shown reflects male, female, and transgender responses only.
9. Extra-genital Chlamydia case reports in BC by gender

Preliminary data and subject to change

Note: Gender is based on the gender variable values collected in Intrahealth Profile EMR which is structured as male, female, transgender and unknown. Data shown reflects male, female, and transgender responses only.
10. Genital Chlamydia case reports in BC by age group

Preliminary data and subject to change

Note: Excludes cases where age could not be calculated due to missing date of birth.
**Gonorrhea**

11. Genital and Extra-genital Gonorrhea case reports in BC by month

Preliminary data and subject to change
12. Genital Gonorrhea case reports in BC by health authority

Preliminary data and subject to change

Note: Excludes missing and unknown geography.
13. Genital Gonorrhea case reports in BC by gender

Preliminary data and subject to change

Note: Gender is based on the gender variable values collected in Intrahealth Profile EMR which is structured as male, female, transgender and unknown. Data shown reflects male, female, and transgender responses only.
14. Extra-genital Gonorrhea case reports in BC by gender

Preliminary data and subject to change

Note: Gender is based on the gender variable values collected in Intrahealth Profile EMR which is structured as male, female, transgender and unknown. Data shown reflects male, female, and transgender responses only.
15. Genital Gonorrhea case reports in BC by age group

![Bar chart showing genital gonorrhea case reports in BC by age group in 2023.](chart)

**Preliminary data and subject to change**

**Note:** Excludes cases where age could not be calculated due to missing date of birth.
HIV

16. New HIV diagnoses in BC by month

Preliminary data and subject to change

Note: There will be a delay in HIV surveillance data while we work on surveillance system data flows and validation. We hope to provide more current data as soon as possible. Until then, data are provided to November 2022 (inclusive).
17. New HIV diagnoses in BC by health authority

Preliminary data and subject to change

Note: Excludes missing and unknown geography.

There will be a delay in HIV surveillance data while we work on surveillance system data flows and validation. We hope to provide more current data as soon as possible. Until then, data are provided to November 2022 (inclusive).
Preliminary data and subject to change

Note: Sex is based on the gender variable values collected in the HIV/AIDS Information System and the sex variable values collected in the laboratory information system. Data shown reflects male and female responses only.

- There will be a delay in HIV surveillance data while we work on surveillance system data flows and validation. We hope to provide more current data as soon as possible. Until then, data are provided to November 2022 (inclusive).
19. New HIV diagnoses in BC by age group

Preliminary data and subject to change

Note: Excludes cases where age could not be calculated due to missing date of birth.

- There will be a delay in HIV surveillance data while we work on surveillance system data flows and validation. We hope to provide more current data as soon as possible. Until then, data are provided to November 2022 (inclusive).
HIV Testing Episodes

20.a. HIV non-prenatal testing episodes* and percent positivity in BC by month - total

Preliminary data and subject to change

*Testing episode = 30-day window (see technical appendix for further details).

Note: Percent positivity is calculated as the number of HIV cases over testing episodes, where a testing episode is defined as a 30-day window.

- There will be a delay in HIV surveillance data while we work on surveillance system data flows and validation. We hope to provide more current data as soon as possible. Until then, data are provided to November 2022 (inclusive).
20.b. HIV non-prenatal testing episodes* and percent positivity in BC by month - female

Preliminary data and subject to change

*Testing episode = 30-day window (see technical appendix for further details).

Note: Percent positivity is calculated as the number of HIV cases over testing episodes, where a testing episode is defined as a 30-day window.

- The number of female HIV cases is based on the gender variable values collected on the HIV case report form and the sex variable reported on the laboratory requisition.

- There will be a delay in HIV surveillance data while we work on surveillance system data flows and validation. We hope to provide more current data as soon as possible. Until then, data are provided to November 2022 (inclusive).
20.c. HIV non-prenatal testing episodes* and percent positivity in BC by month - male

Preliminary data and subject to change

*Testing episode = 30-day window (see technical appendix for further details).

Note: Percent positivity is calculated as the number of HIV cases over testing episodes, where a testing episode is defined as a 30-day window.

-The number of male HIV cases is based on the gender variable values collected on the HIV case report form and the sex variable reported on the laboratory requisition.

-There will be a delay in HIV surveillance data while we work on surveillance system data flows and validation. We hope to provide more current data as soon as possible. Until then, data are provided to November 2022 (inclusive).
Hepatitis C

21. New Hepatitis C cases in BC by month

Preliminary data and subject to change
22. New Hepatitis C cases in BC by health authority

Preliminary data and subject to change

Note: Excludes missing and unknown health authority geography.

The large number of correctional facilities in Fraser Health may attribute Hepatitis C cases to Fraser Health when the cases’ permanent residence may be outside of Fraser Health.
23. New Hepatitis C cases in BC by sex

Preliminary data and subject to change

Note: Sex is based on the sex variable values collected in the laboratory information system. Data shown reflects male and female responses only.
24. New Hepatitis C cases in BC by age group

Preliminary data and subject to change

Note: Excludes cases where age could not be calculated due to missing date of birth.
Hepatitis C Antibody Testing Episodes

25.a. HCV antibody testing episodes* and percent positivity in BC by month - total

Preliminary data and subject to change

*Antibody testing episode = 1-day window (see technical appendix for further details).

Note: Percent positivity is calculated as the number of HCV cases over antibody testing episodes, where an antibody testing episode is defined as a 1-day window.
25.b. HCV antibody testing episodes* and percent positivity in BC by month - female

Preliminary data and subject to change

*Antibody testing episode = 1-day window (see technical appendix for further details).

Note: Percent positivity is calculated as the number of HCV cases over antibody testing episodes, where an antibody testing episode is defined as a 1-day window.

-The number of female HCV antibody testing episodes is based on sex reported on the laboratory requisition. The number of female HCV cases is based on the sex variable values collected in the laboratory information system.
Preliminary data and subject to change

*Antibody testing episode = 1-day window (see technical appendix for further details).

Note: Percent positivity is calculated as the number of HCV cases over antibody testing episodes, where an antibody testing episode is defined as a 1-day window.

-The number of male HCV antibody testing episodes is based on sex reported on the laboratory requisition. The number of male HCV cases is based on the sex variable values collected in the laboratory information system.
Active Tuberculosis

26. Active tuberculosis case reports in BC by month

Preliminary data and subject to change
27. Active tuberculosis case reports in BC by health authority

Preliminary data and subject to change

Note: Excludes missing and unknown geography.
28. Active tuberculosis case reports in BC by sex

Preliminary data and subject to change

Note: Sex is based on the gender variable values collected in Panorama. Data shown reflects male and female responses only.
29. Active tuberculosis case reports in BC by age group

Preliminary data and subject to change

Note: Excludes cases where age could not be calculated due to missing date of birth.
Latent Tuberculosis Infection

30. Latent tuberculosis infection (LTBI) treatment starts in BC by month

Preliminary data and subject to change
Technical Appendix

**Case data:** This report contains preliminary data on infectious syphilis, chlamydia, gonorrhea, HIV, HCV, active tuberculosis, and latent tuberculosis infection. Provincial counts and geographic distribution of cases are expected to change with improvement in data quality and algorithms.

**Testing data:** This report contains non-prenatal HIV and syphilis testing (that is, tests not flagged as a prenatal test) conducted by the BCCDC Public Health Laboratory (PHL). The BCCDC PHL performs >95% of all screening tests for HIV and HCV, and >99% of all tests for syphilis. A test episode for syphilis and HIV consists of all tests for that infection conducted for an individual in a 30-day period (as follow-up or simultaneous test may be required to clarify test results within this period, for example). A test episode for HCV consists of all HCV antibody tests conducted for an individual in a 1-day period.

**Data Sources**

**Infectious syphilis case data:** Data extracted from STIBBI Data Mart (source system = STIIS) and Intrahealth Profile EMR

**Syphilis testing episodes:** Data extracted from STIBBI Data Mart

**Chlamydia:** Data extracted from STIBBI Data Mart (source system = STIIS and Panorama) and Intrahealth Profile EMR

**Gonorrhea:** Data extracted from STIBBI Data Mart (source system = STIIS and Panorama) and Intrahealth Profile EMR

**HIV case data:** Data extracted from STIBBI Data Mart (source system = HAISYS)

**HIV testing episodes:** Data extracted from STIBBI Data Mart

**HCV case data:** Data extracted from STIBBI Data Mart

**HCV testing episodes:** Data extracted from STIBBI Data Mart

**Active tuberculosis case data:** Data extracted from CD Data Mart (source system = Panorama)

**Latent tuberculosis infection data:** Data extracted from CD Data Mart (source system = Panorama)

**British Columbia Case Definitions**

http://www.bccdc.ca/health-professionals/clinical-resources/case-definitions

**Gender Identity**

We acknowledge that both the gender and sex values do not reflect the full spectrum of gender identity and we continue to work towards improving the data collection and reporting of sex and gender.